Ryzumvi^®

• Phentolamine is a relatively non-selective alpha-1 and alpha-2 adrenergic antagonist¹
• Ryzumvi^® (phentolamine ophthalmic solution) 0.75% is approved by the FDA for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists or parasympatholytic agents¹
• Phentolamine ophthalmic solution is being investigated for the treatment of presbyopia, having completed one Phase 2 and one Phase 3 clinical trial^2,3
• Phentolamine ophthalmic solution is being investigated for dim light vision disturbances, with an ongoing Phase 3 clinical trial program^4,5

RYZUMVI is a trademark of OCUPHIRE PHARMA, INC., licensed to the Viatris Companies.
1. RYZUMVI^® (phentolamine ophthalmic solution). Prescribing Information. Available at: https://www.ryzumvi.com/files/prescribing-information.pdf; 2. https://clinicaltrials.gov/study/NCT04675151; 3. https://clinicaltrials.gov/study/NCT05646719; 4. https://clinicaltrials.gov/study/NCT04638660; 5. https://clinicaltrials.gov/study/NCT06349759.